

Trial of Cell Based Therapy for DMD

NCT06692426

Status	RECRUITING
Phase	Phase 1
Sponsor	Masonic Cancer Center, University of Minnesota
Enrollment	8 participants

Key Eligibility Criteria

Inclusion (10)

- Duchenne muscular dystrophy, diagnosed by mutations in the DMD (dystrophin) gene and/or absence of immunohistochemical staining for dystrophin on muscle biopsy
 - Non-ambulatory
 - Intact extensor digitorum brevis (EDB) muscles bilaterally
 - Off investigational therapies for > 30 days
 - Age 18 years of age or older at the time of consent
- ... and 5 more (see full listing online)

Exclusion (3)

- Presence of HLA antibodies directed toward HLA antigens on MyoPAXon
- Active treatment with another investigational therapy
- Known allergy to MyoPAXon components

Locations (1 total)

Masonic Cancer Center, Minneapolis, Minnesota, United States